HDAC9 and familial pancreatic carcinoma: However, “BRCAness” can be pharmacologically induced in cancer cells that do not harbor mutations in DDR genes, as suggested, for example, by previous studies, in which we used HDAC inhibitors to impair DDR molecules in pancreatic cancer cells [25,26].